Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Kenneth Ataga, MD: Crizanlizumab: A New Option for Managing Sickle Cell-Related Pain Crises?

December 30, 2021

Meeting Icon

The first-in-class humanized monoclonal antibody crizanlizumab reduced the rate of sickle cell-related pain crises, compared with placebo. Dr. Ataga discusses results of the SUSTAIN trial.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals